Why Should I Consider Getting a Second Opinion for My JM Child

Learning that your child has Juvenile Myositis may feel overwhelming. Second opinions can confirm a diagnosis, help you understand different treatment options, and review your child’s current treatment plan to ensure it’s the right one for your family.


Dr. Rider is a Pediatric Rheumatologist and Head of the Environmental Autoimmunity Group, National Institute of Environmental Health Science, National Institutes of Health, in Bethesda, Maryland. Dr. Rider is also an esteemed Cure JM Medical Advisory Board member. Since 2008, Dr. Rider has also been a Clinical Professor of Medicine at George Washington University. She sees patients and leads research on juvenile myositis in the Cure JM Center for Excellence and at the National Institute of Health as part of her research studies.

Dr. Dvergsten is a pediatric rheumatologist and physician-scientist who has built his clinical and research career around juvenile myositis. He co-founded Duke’s Myositis Clinic, a designated Cure JM Center of Excellence. He also created and manages a repository for research biospecimens from children with inflammatory myopathies.

Affordable and Accessible Treatments for JM

Affordable and Accessible Treatments for JM

Two special guest speakers, Michelle Vogel, MPA, IV Solutions RX, and Laurel Cherwin, BSN, RN, IgCN, Octapharma, shared information on navigating affordable treatments and care for JM patients.

The FDA’s Ruling on Vamorolone in DMD

You may have heard about yesterday’s FDA ruling, which approved vamorolone as an alternative steroid for use in Duchenne muscular dystrophy.

Vamorolone is a new steroid alternative with fewer side effects than prednisone. The drug aims to preserve the beneficial anti-inflammatory and muscle-strengthening characteristics of corticosteroids, while decreasing some of the unwelcome side effects, including bone fragility, delayed growth, and behavior changes.

As we learned in yesterday’s announcement, vamorolone was found to be both safe and effective as a therapy for Duchenne muscular dystrophy in its newly approved indication.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!